International stocks trading in New York closed higher on Thursday.
The S&P/BNY Mellon index of American depositary receipts rose 1.1% to 135.35. The European index rose 0.9% to 125.80. The Asian index rose 1.3% to 156.61. The Latin American index rose 1.9% to 236.24. And the emerging-markets index rose 1.7% to 288.63.
Amarin Corp. (AMRN) was among those with ADRs that traded actively.
Amarin said the Food and Drug Administration plans to hold an advisory committee meeting to discuss whether heart-disease drug Vascepa's label should be expanded. The FDA's surprise decision to convene the meeting means a three-month delay in the agency's decision on the label expansion, until December, Amarin says. Amarin is asking the FDA to tweak Vascepa's label to reflect clinical trial results indicating the drug reduced the risk of heart attacks, strokes and deaths in certain high-risk patients. Such an addition could turn Vascepa into a blockbuster, analysts say, and Amarin has been preparing by increasing the size of its sales force. ADRs, which had closed up 5.6%, fell 22% to $13.94 in after-hours trading.
AngloGold Ashantireported a massive rise in net profit for the first half of the year after booking a large charge last year, and said it expects a seasonally stronger second half. ADRs closed down 2% at $20.56.
Building materials supplier James Hardie Industries first-quarter net profit fell by 5%, but management signaled its full-year earnings outlook was broadly consistent with market expectations. ADRs closed down 0.3% at $13.21.
(MORE TO FOLLOW) Dow Jones Newswires